Levetiracetam
Product Images NDC 70166-081

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70166-081). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lohxa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Label)

Levetiracetam oral solution USP, 500 mg/5 mL strength in a 50 units x 5 mL package by Lohxa. The label shows administration is for oral use only, includes storage instructions at controlled room temperature 20 to 25 °C, and features the Lohxa logo with their website. The product NDC is 70166-081-02.*

FDA Label Image

Figure.jpg (Figure)

Bar chart depicting the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The chart shows higher patient percentages for both Levetiracetam doses compared to placebo, with the 3000 mg/day group slightly higher than the 1000 mg/day group.*

FDA Label Image

Figure1.jpg (Figure1)

A bar chart showing the percentage of patients for three groups: Placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). The vertical axis represents % of patients and the horizontal axis lists the treatment groups and their sample sizes.*

FDA Label Image

Figure2.jpg (Figure2)

A bar chart comparing the percentage of patients between placebo and Levetiracetam 3000 mg/day groups. The placebo group (N=104) shows about 14.4% of patients, while the Levetiracetam group (N=180) shows about 39.4% of patients, indicating a higher response rate in the Levetiracetam group.*

FDA Label Image

Figure3.jpg (Figure3)

A bar chart comparing the percentage of patients responding in two groups: placebo (N=97) and levetiracetam (N=101). The levetiracetam group shows a higher response rate of 44.6% compared to 19.6% for placebo. The y-axis represents the percentage of patients, ranging from 0% to 45%.*

FDA Label Image

Figure4.jpg (Figure4)

A bar graph comparing the percentage of a certain measure between placebo and Levetiracetam groups, showing approximately 45.2% for placebo (N=84) and 72.2% for Levetiracetam (N=79).*

FDA Label Image

Figure5 (Figure5)

A bar chart comparing the percentage of patients between two groups, illustrating values of 19.6% and 43.1%. The y-axis represents the percent of patients ranging from 0% to 45%. Asterisk indicates statistical significance for the higher percentage group.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure diagram of Levetiracetam, showing its molecular formula with labeled atoms including carbon (C), hydrogen (H), nitrogen (N), and oxygen (O). The diagram displays the characteristic pyrrolidone ring and the side chains consistent with Levetiracetam's structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.